Product Description

Type 2 Diabetes is more than 2-fold higher in individuals with NAFLD and often evolves with normal liver enzymes.

LIVERFAStTM accurately identifies severe fibrosis and cirrhosis in both patients with or without type 2 diabetes irrespective of liver enzyme levels.

NASH related cirrhosis is disproportionately high in those with type 2 diabetes and is now on a trajectory to become the most common indication for liver transplantation in the U.S.

LIVERFAStTM accurately identifies cirrhosis in subjects with all biochemistry inside the normal laboratory range.

Product Brochure

Product Information

Interested in this product?

Request a call-back